Eris-Natco tie-up to launch semaglutide generic as India market heats up

đŸ’¡Analysis & Context
Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as rising demand and impending patent expiry fuel intense Monitor developments in Eris-Natco for further updates.
đŸ“‹ Quick Summary
Eris Lifesciences partners with Natco Pharma to commercialise semaglutide in India in 2026, as risin
Original Source:
Read full article at sourceHelp us improve this article. Share your feedback and suggestions.


